New Limit

New Limit, founded in 2021, has raised approximately $240 million across Seed to latest funding rounds, including a $45 million round valuing the company at $1.6 billion. Headquartered in Boston, Massachusetts, United States, New Limit develops precision therapeutics using genomics and biomarker-driven approaches. Key investors include Kleiner Perkins. Since inception, the company has built a targeted therapy pipeline spanning oncology and metabolic disorders. With strong investor backing and advanced clinical programs, New Limit is positioned to expand its precision medicine platform and accelerate patient-focused treatment development.